Abstract
Malignant hyperthermia (MH) can be fatal if the crisis is not appropriately treated. It is an inherited disease usually triggered by the administration of volatile inhalational anesthetics and/or succinylcholine, a muscle relaxant. In a patient with suspected MH, the mechanism of calcium release from storage in the sarcoplasmic reticulum in the skeletal muscle is abnormally accelerated. Unexplained hypercarbia representing >55 mmHg of end-tidal carbon dioxide, tachycardia, and muscle rigidity (including masseter muscle rigidity) are early signs of the initiation of MH, because the metabolism is accelerated. The body temperature can rise by >0.5 °C/15 min and may reach ≥40 °C. Respiratory and metabolic acidosis, arrhythmia, cola-colored urine, increased levels of serum potassium, and tented T-waves on electrocardiogram are common and can lead to cardiac arrest. MH should be treated by discontinuation of the triggering agents, administration of intravenous dantrolene (initially 1 mg/kg), and reduction of the body temperature. Early diagnosis and sufficient dantrolene with body temperature reduction are essential to relieve the patient’s MH crisis. This guideline in Japanese translation has been posted on the website: http://www.anesth.or.jp/guide/pdf/guideline_akuseikounetsu.pdf.
Abbreviations
- MH:
-
Malignant hyperthermia
- PMH:
-
Postoperative malignant hyperthermia
References
Harrison GG. Control of the malignant hyperpyrexia syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 1975;47:62–5.
Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. A multicenter study. Anesthesiology. 1982;56:254–62.
Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771–9.
Morio M, Kikuchi H, Yuge O, Murata K, Fujioka Y, Mukaida K, Mori K. Clinical criteria of malignant hyperthermia – Revised criteria (in Japanese with English abstract). Anesth Resusc. 1988;24(Supple 11):104–10.
Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118:381–7.
Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014;118:388–96.
Glahn KP, Ellis FR, Halsall PJ, Müller CR, Snoeck MM, Urwyler A, Wappler F. European malignant hyperthermia group. recognizing and managing a malignant hyperthermia crisis: guidelines from the European malignant hyperthermia group. Br J Anaesth. 2010;105:417–20.
Lin HT, Wang SC1, Zuo Z, Tsou MY, Chan KH, Yuan HB. Increased requirement for minute ventilation and negative arterial to end-tidal carbon dioxide gradient may indicate malignant hyperthermia. J Chin Med Assoc. 2014;77:209–12.
Kwetny I, Finucane BT. Anesth Analg. Negative arterial to end-tidal carbon dioxide gradient: an additional sign of malignant hyperthermia during desflurane anesthesia. Anesth Analg. 2006;102:815–7.
Jones C, Bennett K, Kim TW, Bulger TF, Pollock N. Preparation of Datex-Ohmeda Aestiva and Aisys anaesthetic machines for use in malignant hyperthermia susceptible patients. Anaesth Intensive Care. 2012;40:490–7.
Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry. Anesth Analg. 2014;118:369–74.
Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology. 2007;106:901–6.
Bandschapp O, Girard T. Malignant hyperthermia. Swiss Med Wkly. 2012;142:w13652.
Migita T, Mukaida K, Hamada H, Kawamoto M. Analysis of postoperative malignant hyperthermia (in Japanese with English abstract). Anesth Resusc. 2013;49:7–11.
Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia: an analysis of cases from the north American malignant hyperthermia registry. Anesthesiology. 2008;109:825–9.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93.
Tobin JR, Jason DR, Challa VR, Nelson TE, Sambuughin N. Malignant hyperthermia and apparent heat stroke. JAMA. 2001;11:168–9.
Thomas J, Crowhurst T. Exertional heat stroke, rhabdomyolysis and susceptibility to malignant hyperthermia. Intern Med J. 2013;43:1035–8.
Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg EJ, Drost G, Quinlivan R, Snoeck M, Norwood F, Radunovic A, Straub V, Roberts M, Vrancken AF, van der Pol WL, de Coo RI, Manzur AY, Yau S, Abbs S, King A, Lammens M, Hopkins PM, Mohammed S, Treves S, Muntoni F, Wraige E, Davis MR, van Engelen B, Jungbluth H. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord. 2013;23:540–8.
Sagui E, Montigon C, Abriat A, Jouvion A, Duron-Martinaud S, Canini F, Zagnoli F, Bendahan D, Figarella-Branger D, Brégigeon M, Brosset C. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia? PLoS One. 2015;10:e0135496.
Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg. 1997;84:1038–41.
Malandrini A, Orrico A, Gaudiano C, Gambelli S, Galli L, Berti G, Tegazzin V, Dotti MT, Federico A, Sorrentino V. Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia. Anesthesiology. 2008;109:625–8.
Mukaida K, Kawamoto M. Malignant Hyperthermia-up-to-date topics (in Japanese with English abstract). J Jpn Soc Clin Anesth. 2012;32:682–90.
Monsieurs KG, Van Broeckhoven C, Martin JJ, Van Hoof VO, Heytens L. Gly341Arg mutation indicating malignant hyperthermia susceptibility: specific cause of chronically elevated serum creatine kinase activity. J Neurol Sci. 1998;154:62–5.
Sano K, Miura S, Fujiwara T, ujioka R, Yorita A, Noda K, Kida H, Azuma K, Kaieda S, Yamamoto K, Taniwaki T, Fukumaki Y, Shibata H. Novel missense mutation of RYR1 in familial idiopathic hyper CK-emia. J Neurol Sci. 2015;356:142–7.
Brislin RP, Theroux MC. Core myopathies and malignant hyperthermia susceptibility: a review. Paediatr Anaesth. 2013;23:834–41.
Maggi L, Scoto M, Cirak S, Robb SA, Klein A, Lillis S, Cullup T, Feng L, Manzur AY, Sewry CA, Abbs S, Jungbluth H, Muntoni F. Congenital myopathies—clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom. Neuromuscul Disord. 2013;23:195–205.
Weigl LG, Hohenegger M, Kress HG. Dihydropyridine-induced Ca2+ release from ryanodine-sensitive Ca2+ pools in human skeletal muscle cells. J Physiol. 2000;525(Pt 2):461–9.
Migita T, Mukaida K, Yasuda T, Hamada H, Kawamoto M. Calcium channel blockers are inadequate for malignant hyperthermia crisis. J Anesth. 2012;26:579–84.
Wappler F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol. 2010;23:417–22.
Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice. Anesthesiology. 2011;114:205–12.
Kim TW, Wingate JR, Fernandez AM, Whitaker E, Tham RQ. Washout times of desflurane, sevoflurane and isoflurane from the GE Healthcare Aisys® and Avance®, Carestation®, and Aestiva® anesthesia system. Paediatr Anaesth. 2013;23:1124–30.
Barnes C, Stowell KM, Bulger T, Langton E, Pollock N. Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update. Anaesth Intensive Care. 2015;43:98–104.
Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth. 2000;85:118–28.
Paasuke RT, Brownell AK. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia. JAMA. 1986;255:769–71.
Wappler F, Fiege M, Antz M, Schulte Am Esch J. Hemodynamic and metabolic alterations in response to graded exercise in a patient susceptible to malignant hyperthermia. Anesthesiology. 2000;92:268–72.
Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, Matschke J, Schulte Am Esch J. Evidence for susceptibility to malignant hyperthermia in patients with stress-induced rhabdomyolysis. Anesthesiology. 2001;94:95–100.
López JR, Rojas B, Gonzalez MA, Terzic A. Myoplasmic Ca2+ concentration during exertional rhabdomyolysis. Lancet. 1995;345:424–5.
Tobin JR, Jason DR, Challa VR, Nelson TE, Sambuughin N. Malignant hyperthermia and apparent heat stroke. JAMA. 2001;286:168–9.
Hackl W, Winkler M, Mauritz W, Sporn P, Steinbereithner K. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Br J Anaesthesia. 1991;66:138–40.
Allen GC. Oral dantrolene. Anaesthesia. 2004;59:1139–40.
Allen GC, Cattran CB, Peterson RG, Lalande M. Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients. Anesthesiology. 1988;69:900–4.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
Fujioka Y, Matsui K, Mukaida K, Yuge O, Kikuchi H, Morio M. Effect of lidocaine on Ca2+ recruitment in the skinned skeletal muscle of the guinea pig (in Japanese with English abstract). Anesth Resusc. 1988;24(Supple 19):19–23.
Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;2(7679):895–8.
Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology. 1993;79:5–9.
Mukaida K, Yuge O. Diagnosis of malignant hyperthermia In: Kikuchi H, editor. Malignant hyperthermia for professional anesthesiologists (Japanese). Kokuseido; 2006. pp.155–8.
Ibarra CAM, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi YK, Ochiai R, Nishino I. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology. 2006;104:1146–54.
Acknowledgements
This guideline was the achievement by Masashi Kawamoto, Keiko Mukaida, Yasuko Ichihara, Shiroh Isono, and Hirosato Kikuchi, Malignant Hyperthermia working group of Safety Committee, the Japanese Society of Anesthesiologists.
Author information
Authors and Affiliations
Consortia
About this article
Cite this article
Safety Committee of Japanese Society of Anesthesiologists. JSA guideline for the management of malignant hyperthermia crisis 2016. J Anesth 31, 307–317 (2017). https://doi.org/10.1007/s00540-016-2305-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00540-016-2305-z